Spyre Therapeutics, Inc.

NASDAQ:SYRE

Biotechnology

Healthcare
$101.46 +1.38%

+$1.21 today

Market cap
$9.64B
Beta
3.06
P/E (TTM)
-171.1
EPS (TTM)
-$0.52
52W Low $14.00High $91.04

Volume 1.37M

Average 1.17M

SYRE Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Spyre Therapeutics, Inc.NASDAQ: SYRE

Income Tax Expense · Q3 FY2026 · quarter ended Sep 2026

Income tax expense remains negative

Q3 FY2026 income tax expense was $0, compared with $0 a year earlier. Trailing-twelve-month income tax expense was $0.

Context

  • Income tax expense increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly income tax expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
-$15K-129.4% YoY
LTMSep 2026
$0+100.0% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-129.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
(15K) USD
Year-over-year change
-129.4%

Income Tax Expense vs competitors

How SYRE compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +100.0% is the 4th highest of 5, against a peer median of +118.0%.
  • Income tax expense amounts to 0.0% of revenue for SYRE, versus a peer median of 0.0%.
SYRE Competitors
Income Tax Expense for SYRE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABVXAbivax S.A.FY2025€5.85M EUR———
ANABAnaptysBio, Inc.LTM Mar 2026$160K USD+240.4%+89.8%0.1%
ARDXArdelyx, Inc.LTM Mar 2026$118K USD-88.2%+394.8%0.0%
IFRXInflaRx N.V.LTM Mar 2026€12.28K EUR+135.4%—41.9%
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024€4K EUR+100.6%——
SYRESpyre Therapeutics, Inc.LTM Sep 2026$0 USD+100.0%—0.0%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
UPBUpstream Bio, Inc.LTM Mar 2026$0 USD——0.0%
IMUXImmunic, Inc.LTM Mar 2026$0 USD———
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding SYRE) —+118.0%+242.3%0.0%

Competitors are the stored peer set for SYRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.74M2.33M886K00
Cost of Revenue0000171.65M
Gross Profit18.74M2.33M886K0(171.65M)
Gross Margin100.0%100.0%100.0%——
Research & Development57.07M58.58M89.5M162.79M171.65M
Selling, General & Admin27.32M28.53M39.95M45.78M47.91M
Operating Expenses84.39M87.11M243.19M208.57M37.91M
Depreciation & Amortization1.58M1.96M744K010M
EBITDA(64.08M)(81.99M)(127.82M)(207.97M)(209.56M)
EBITDA Margin-342.0%-3520.3%-14426.6%——
Operating Income(65.65M)(84.78M)(242.3M)(208.57M)(209.56M)
Operating Margin-350.3%-3640.2%-27348.0%——
Interest Income111K837K6.15M21.31M24.89M
Interest Expense00000
Other Income / Expenses(11K)830K(96.51M)599K54.34M
Income Before Tax(65.66M)(83.95M)(338.82M)(207.97M)(155.22M)
Pre-Tax Margin-350.4%-3604.6%-38241.1%——
Income Tax Expense141K(136K)(26K)51K(15K)
Net Income(65.8M)(83.82M)(338.79M)(208.02M)(155.2M)
Net Margin-351.1%-3598.8%-38238.1%——
EPS (Basic)(25.02)(24.86)(46.15)(3.18)(1.98)
EPS (Diluted)(25.02)(24.86)(46.15)(3.18)(1.98)
Weighted Avg Shares2.63M3.37M6.9M47.03M64.06M
Weighted Avg Shares (Diluted)2.63M3.37M6.9M47.03M64.06M

Spyre Therapeutics, Inc.

NASDAQ:SYRE

Intrinsic Alpha fair value

Locked

Current Price

$101.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.